| Abstract [eng] |
Matrix metalloproteinases (MMP) are a family of proteolytic enzymes; these enzymes participate in tumour angiogenesis, processes of tumour growth and development of metastases. Therefore, it is important to evaluate the changes of expression of these enzymes in cancer patients. The aim of this study – to assess the expression of MMP genes and single nucleotide polymorphism in promoter sequences of MMP genes in breast and prostate cancer and evaluate parameters investigated regarding prognosis. The perspective study included 88 female patients with breast cancer and 82 patients with prostate cancer. MMP-9 and MMP-11 gene expression was examined and MMP-3 (-1171 5A/6A), MMP-9 (-1562 C/T) polymorphism was evaluated in the blood of breast cancer patients; MT1-MMP, MMP-1, MMP-2, MMP-3, MMP-9, MMP-11, MMP-13 gene expression was examined in the tumours. MMP-9, MMP-11 gene expression and MMP-9 (-1562 C/T) polymorphism were examined in the blood of prostate cancer patients. The results of the study show that MMP gene expression is related to clinical and pathological characteristics of breast and prostate cancer patients. MMP-3 (-1171 5A/6A) polymorphism is a prognostic factor of survival of breast cancer patients; while MMP-11 gene expression in blood is a prognostic factor of survival of prostate cancer patients. |
